Elizabeth Blair
Concepts (341)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Squamous Cell | 19 | 2019 | 1002 | 1.730 |
Why?
| Head and Neck Neoplasms | 24 | 2017 | 972 | 1.680 |
Why?
| Salivary Gland Neoplasms | 5 | 2019 | 57 | 1.490 |
Why?
| Carcinoma, Mucoepidermoid | 2 | 2019 | 15 | 1.470 |
Why?
| Chemoradiotherapy | 14 | 2022 | 290 | 1.140 |
Why?
| Neoplasm Recurrence, Local | 12 | 2019 | 1149 | 1.010 |
Why?
| Oropharyngeal Neoplasms | 6 | 2022 | 118 | 0.920 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2022 | 2240 | 0.920 |
Why?
| Mouth Neoplasms | 7 | 2018 | 173 | 0.800 |
Why?
| Paranasal Sinus Diseases | 2 | 2018 | 23 | 0.790 |
Why?
| Gene Rearrangement | 2 | 2019 | 167 | 0.770 |
Why?
| Papillomavirus Infections | 5 | 2022 | 196 | 0.770 |
Why?
| Neoplasm Grading | 1 | 2019 | 317 | 0.710 |
Why?
| Laryngeal Diseases | 2 | 2015 | 15 | 0.700 |
Why?
| Nose Diseases | 1 | 2017 | 10 | 0.690 |
Why?
| Nose Neoplasms | 1 | 2017 | 31 | 0.690 |
Why?
| Maxillary Sinus | 2 | 2018 | 26 | 0.660 |
Why?
| Nasal Cavity | 1 | 2017 | 90 | 0.660 |
Why?
| Trans-Activators | 1 | 2019 | 427 | 0.630 |
Why?
| Paranasal Sinus Neoplasms | 1 | 2016 | 22 | 0.610 |
Why?
| Aspergillosis | 1 | 2016 | 45 | 0.600 |
Why?
| Cementoma | 1 | 2015 | 2 | 0.600 |
Why?
| Mandibular Neoplasms | 1 | 2015 | 25 | 0.590 |
Why?
| Sarcoidosis | 1 | 2015 | 88 | 0.550 |
Why?
| Papillomaviridae | 4 | 2022 | 141 | 0.550 |
Why?
| Laryngeal Neoplasms | 5 | 2017 | 82 | 0.540 |
Why?
| Sjogren's Syndrome | 3 | 2009 | 28 | 0.510 |
Why?
| Salivary Glands, Minor | 2 | 2009 | 10 | 0.500 |
Why?
| Middle Aged | 43 | 2022 | 24750 | 0.480 |
Why?
| Aged, 80 and over | 21 | 2020 | 6383 | 0.460 |
Why?
| Otolaryngology | 1 | 2012 | 38 | 0.450 |
Why?
| Airway Management | 1 | 2012 | 33 | 0.450 |
Why?
| Female | 51 | 2022 | 43278 | 0.440 |
Why?
| Humans | 68 | 2022 | 80834 | 0.420 |
Why?
| Adult | 39 | 2022 | 25137 | 0.410 |
Why?
| Placenta | 1 | 2011 | 196 | 0.400 |
Why?
| Aged | 34 | 2020 | 17903 | 0.390 |
Why?
| Anesthesiology | 1 | 2012 | 157 | 0.390 |
Why?
| Quinazolines | 4 | 2012 | 213 | 0.390 |
Why?
| Male | 48 | 2022 | 40407 | 0.380 |
Why?
| Induction Chemotherapy | 6 | 2022 | 140 | 0.380 |
Why?
| Disease-Free Survival | 15 | 2020 | 1157 | 0.360 |
Why?
| Neck | 2 | 2020 | 88 | 0.340 |
Why?
| Head | 2 | 2020 | 115 | 0.330 |
Why?
| Hydroxyurea | 9 | 2012 | 228 | 0.330 |
Why?
| Radiotherapy, Intensity-Modulated | 5 | 2016 | 167 | 0.320 |
Why?
| Clinical Competence | 1 | 2012 | 684 | 0.310 |
Why?
| Radiotherapy Dosage | 11 | 2020 | 463 | 0.300 |
Why?
| Warts | 2 | 2019 | 11 | 0.300 |
Why?
| Fluorouracil | 9 | 2012 | 537 | 0.290 |
Why?
| Tongue Neoplasms | 4 | 2018 | 51 | 0.280 |
Why?
| Nasopharyngeal Neoplasms | 2 | 2016 | 44 | 0.280 |
Why?
| Diagnosis, Differential | 4 | 2017 | 1546 | 0.280 |
Why?
| Alphapapillomavirus | 2 | 2021 | 38 | 0.260 |
Why?
| Treatment Outcome | 17 | 2022 | 7653 | 0.260 |
Why?
| Antineoplastic Agents | 6 | 2012 | 2276 | 0.260 |
Why?
| Neoplasm Staging | 12 | 2016 | 1872 | 0.240 |
Why?
| Paclitaxel | 5 | 2022 | 455 | 0.240 |
Why?
| Laryngostenosis | 1 | 2021 | 13 | 0.230 |
Why?
| Tracheal Stenosis | 1 | 2021 | 22 | 0.230 |
Why?
| Carcinoma | 2 | 2016 | 439 | 0.220 |
Why?
| Drug Monitoring | 1 | 2022 | 109 | 0.220 |
Why?
| Carcinoma, Papillary, Follicular | 1 | 2020 | 11 | 0.220 |
Why?
| DNA, Viral | 1 | 2022 | 275 | 0.220 |
Why?
| Respiratory System | 1 | 2021 | 112 | 0.210 |
Why?
| In Situ Hybridization, Fluorescence | 2 | 2019 | 356 | 0.210 |
Why?
| ras Proteins | 1 | 2020 | 128 | 0.200 |
Why?
| Smoking | 3 | 2014 | 544 | 0.200 |
Why?
| Follow-Up Studies | 13 | 2019 | 3717 | 0.200 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 132 | 0.200 |
Why?
| Lymph Nodes | 2 | 2016 | 517 | 0.200 |
Why?
| Risk Factors | 8 | 2019 | 5257 | 0.200 |
Why?
| Retrospective Studies | 15 | 2018 | 7532 | 0.200 |
Why?
| Arteries | 1 | 2020 | 174 | 0.200 |
Why?
| Practice Guidelines as Topic | 2 | 2017 | 1043 | 0.190 |
Why?
| Thyroid Neoplasms | 2 | 2020 | 431 | 0.190 |
Why?
| Heterocyclic Compounds | 1 | 2019 | 15 | 0.190 |
Why?
| Immunologic Deficiency Syndromes | 1 | 2019 | 41 | 0.190 |
Why?
| Young Adult | 6 | 2022 | 5780 | 0.190 |
Why?
| Radiation Dosage | 1 | 2020 | 219 | 0.190 |
Why?
| Prognosis | 9 | 2022 | 3603 | 0.190 |
Why?
| Lip | 2 | 2009 | 14 | 0.190 |
Why?
| Bone Cysts, Aneurysmal | 1 | 2018 | 7 | 0.190 |
Why?
| Receptors, CXCR4 | 1 | 2019 | 41 | 0.190 |
Why?
| Combined Modality Therapy | 9 | 2016 | 1628 | 0.180 |
Why?
| Precancerous Conditions | 2 | 2016 | 191 | 0.180 |
Why?
| Ubiquitin Thiolesterase | 1 | 2018 | 54 | 0.180 |
Why?
| Orthodontic Appliances | 1 | 2018 | 8 | 0.180 |
Why?
| Dental Alloys | 1 | 2018 | 7 | 0.180 |
Why?
| Deglutition | 3 | 2020 | 69 | 0.180 |
Why?
| Inflammation | 2 | 2017 | 795 | 0.180 |
Why?
| Child | 6 | 2019 | 6587 | 0.170 |
Why?
| Glottis | 1 | 2017 | 9 | 0.170 |
Why?
| Adolescent | 7 | 2022 | 8878 | 0.170 |
Why?
| Bone Marrow | 1 | 2019 | 401 | 0.170 |
Why?
| Life Style | 1 | 2018 | 182 | 0.160 |
Why?
| Hypopharyngeal Neoplasms | 2 | 2011 | 15 | 0.160 |
Why?
| Fibrosis | 1 | 2017 | 188 | 0.160 |
Why?
| Prospective Studies | 7 | 2022 | 3961 | 0.160 |
Why?
| Transcriptome | 1 | 2020 | 513 | 0.160 |
Why?
| Neoplasm Invasiveness | 3 | 2016 | 512 | 0.150 |
Why?
| Fibroma, Ossifying | 1 | 2015 | 5 | 0.150 |
Why?
| Time Factors | 4 | 2019 | 5282 | 0.150 |
Why?
| Anticarcinogenic Agents | 1 | 2016 | 72 | 0.150 |
Why?
| Guideline Adherence | 1 | 2017 | 216 | 0.150 |
Why?
| Premedication | 1 | 1995 | 57 | 0.150 |
Why?
| Pleural Neoplasms | 1 | 2017 | 171 | 0.150 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 1164 | 0.140 |
Why?
| Cerebellopontine Angle | 1 | 1994 | 6 | 0.140 |
Why?
| Ulnar Nerve | 1 | 1994 | 6 | 0.140 |
Why?
| Neuroma, Acoustic | 1 | 1994 | 16 | 0.140 |
Why?
| Tumor Virus Infections | 1 | 2014 | 79 | 0.140 |
Why?
| Predictive Value of Tests | 1 | 2019 | 1705 | 0.130 |
Why?
| Maximum Tolerated Dose | 3 | 2012 | 259 | 0.130 |
Why?
| Neuromuscular Blocking Agents | 1 | 1994 | 35 | 0.130 |
Why?
| Leukoplakia, Oral | 1 | 2013 | 9 | 0.130 |
Why?
| Facial Nerve | 1 | 1994 | 35 | 0.130 |
Why?
| Aminolevulinic Acid | 1 | 2013 | 21 | 0.130 |
Why?
| Anti-Bacterial Agents | 2 | 1999 | 796 | 0.130 |
Why?
| Photosensitizing Agents | 1 | 2013 | 47 | 0.130 |
Why?
| Carboplatin | 3 | 2022 | 267 | 0.130 |
Why?
| Biopsy | 4 | 2009 | 1150 | 0.130 |
Why?
| Mouth | 2 | 2011 | 51 | 0.120 |
Why?
| Monitoring, Intraoperative | 1 | 1994 | 141 | 0.120 |
Why?
| Photochemotherapy | 1 | 2013 | 96 | 0.120 |
Why?
| Pain | 1 | 2015 | 354 | 0.120 |
Why?
| Radiation-Sensitizing Agents | 1 | 2012 | 100 | 0.120 |
Why?
| Education, Medical, Graduate | 1 | 2016 | 330 | 0.120 |
Why?
| Deglutition Disorders | 2 | 2011 | 82 | 0.120 |
Why?
| Lymph Node Excision | 1 | 2013 | 196 | 0.110 |
Why?
| Radiotherapy | 2 | 2011 | 335 | 0.110 |
Why?
| Research Design | 2 | 2013 | 545 | 0.110 |
Why?
| Survival Analysis | 5 | 2018 | 1535 | 0.110 |
Why?
| Chemoradiotherapy, Adjuvant | 1 | 2011 | 35 | 0.110 |
Why?
| Chemotherapy, Adjuvant | 5 | 2012 | 445 | 0.110 |
Why?
| Protein Kinase Inhibitors | 1 | 2016 | 532 | 0.110 |
Why?
| Tracheotomy | 1 | 2011 | 17 | 0.110 |
Why?
| Organ Preservation | 1 | 2011 | 71 | 0.110 |
Why?
| Survival Rate | 4 | 2019 | 1852 | 0.110 |
Why?
| Speech | 1 | 2010 | 72 | 0.100 |
Why?
| Brain Diseases | 1 | 2011 | 184 | 0.100 |
Why?
| Genetic Predisposition to Disease | 1 | 2019 | 2168 | 0.100 |
Why?
| Vocal Cords | 1 | 2009 | 18 | 0.100 |
Why?
| Airway Obstruction | 1 | 2011 | 112 | 0.100 |
Why?
| Agammaglobulinemia | 1 | 2010 | 21 | 0.100 |
Why?
| Quality of Life | 3 | 2012 | 1335 | 0.100 |
Why?
| Developmental Disabilities | 1 | 2011 | 176 | 0.100 |
Why?
| Emergency Medical Services | 1 | 2012 | 177 | 0.100 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2009 | 368 | 0.100 |
Why?
| Kaplan-Meier Estimate | 4 | 2013 | 868 | 0.090 |
Why?
| Cohort Studies | 5 | 2018 | 2627 | 0.090 |
Why?
| Radiotherapy, High-Energy | 1 | 2008 | 50 | 0.090 |
Why?
| United States | 6 | 2018 | 6156 | 0.090 |
Why?
| Confidence Intervals | 4 | 2018 | 227 | 0.090 |
Why?
| Enteral Nutrition | 2 | 2020 | 103 | 0.090 |
Why?
| Neck Dissection | 4 | 2010 | 70 | 0.090 |
Why?
| Myelitis, Transverse | 1 | 2008 | 9 | 0.090 |
Why?
| Submandibular Gland Diseases | 1 | 2008 | 9 | 0.090 |
Why?
| Genomics | 1 | 2014 | 631 | 0.090 |
Why?
| Neoplasms, Second Primary | 1 | 2011 | 247 | 0.090 |
Why?
| Military Personnel | 1 | 2009 | 76 | 0.090 |
Why?
| Neoadjuvant Therapy | 2 | 2012 | 265 | 0.090 |
Why?
| Neuromyelitis Optica | 1 | 2008 | 16 | 0.090 |
Why?
| Skin | 1 | 2012 | 540 | 0.090 |
Why?
| Aortic Aneurysm | 1 | 1988 | 81 | 0.090 |
Why?
| Fatal Outcome | 2 | 2019 | 290 | 0.080 |
Why?
| Risk Assessment | 5 | 2016 | 2205 | 0.080 |
Why?
| Taxoids | 1 | 2007 | 125 | 0.080 |
Why?
| Sinus Thrombosis, Intracranial | 1 | 2006 | 11 | 0.080 |
Why?
| DNA | 1 | 2012 | 1253 | 0.080 |
Why?
| Tinnitus | 1 | 2006 | 19 | 0.080 |
Why?
| Headache | 1 | 2006 | 67 | 0.080 |
Why?
| Incidence | 3 | 2018 | 1593 | 0.080 |
Why?
| Prodrugs | 2 | 1996 | 47 | 0.080 |
Why?
| Drug Administration Schedule | 4 | 2016 | 926 | 0.070 |
Why?
| Infant, Newborn | 1 | 2011 | 2352 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 3 | 2019 | 1991 | 0.070 |
Why?
| Antibodies, Monoclonal | 2 | 2010 | 1466 | 0.070 |
Why?
| Drug Therapy, Combination | 3 | 1999 | 969 | 0.070 |
Why?
| Cisplatin | 2 | 2022 | 559 | 0.070 |
Why?
| Gastroesophageal Reflux | 2 | 2009 | 110 | 0.070 |
Why?
| Pregnancy | 1 | 2011 | 2717 | 0.070 |
Why?
| Adenocarcinoma | 1 | 2011 | 1132 | 0.070 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2017 | 99 | 0.070 |
Why?
| Radiotherapy, Adjuvant | 3 | 2010 | 295 | 0.060 |
Why?
| Internship and Residency | 1 | 2012 | 887 | 0.060 |
Why?
| Tomography, X-Ray Computed | 2 | 2011 | 2479 | 0.060 |
Why?
| Remission Induction | 2 | 2016 | 690 | 0.060 |
Why?
| Retreatment | 2 | 2012 | 106 | 0.060 |
Why?
| Immunohistochemistry | 3 | 2017 | 1766 | 0.060 |
Why?
| Pulmonary Surgical Procedures | 1 | 2021 | 8 | 0.060 |
Why?
| Alcohol Drinking | 2 | 2018 | 273 | 0.060 |
Why?
| Gene Expression Profiling | 2 | 2020 | 1322 | 0.060 |
Why?
| Receptor, Endothelin A | 1 | 2021 | 22 | 0.060 |
Why?
| Clinical Trials, Phase II as Topic | 2 | 2013 | 166 | 0.060 |
Why?
| Endothelial Growth Factors | 1 | 2001 | 56 | 0.060 |
Why?
| Respiratory Function Tests | 1 | 2021 | 145 | 0.060 |
Why?
| Lymphokines | 1 | 2001 | 108 | 0.060 |
Why?
| Constriction, Pathologic | 1 | 2021 | 208 | 0.050 |
Why?
| Periodontal Diseases | 1 | 2000 | 9 | 0.050 |
Why?
| Lymphoid Tissue | 1 | 2000 | 55 | 0.050 |
Why?
| Radiography | 2 | 2014 | 842 | 0.050 |
Why?
| Hyperplasia | 1 | 2000 | 146 | 0.050 |
Why?
| Bronchoscopy | 1 | 2021 | 146 | 0.050 |
Why?
| Antibodies, Monoclonal, Humanized | 3 | 2011 | 891 | 0.050 |
Why?
| Disease Progression | 2 | 2017 | 1430 | 0.050 |
Why?
| Clindamycin | 2 | 1999 | 15 | 0.050 |
Why?
| Cefuroxime | 2 | 1996 | 3 | 0.050 |
Why?
| Feasibility Studies | 1 | 2022 | 729 | 0.050 |
Why?
| Tonsillectomy | 1 | 1999 | 27 | 0.050 |
Why?
| Patient-Centered Care | 1 | 2021 | 175 | 0.050 |
Why?
| Carcinoma, Papillary | 1 | 2001 | 182 | 0.050 |
Why?
| Benzylamines | 1 | 2019 | 14 | 0.050 |
Why?
| Neoplasms, Squamous Cell | 1 | 2019 | 19 | 0.050 |
Why?
| Aortic Rupture | 2 | 1990 | 51 | 0.050 |
Why?
| Bone Marrow Examination | 1 | 2019 | 51 | 0.050 |
Why?
| Patient Care Team | 1 | 2021 | 260 | 0.050 |
Why?
| Antibiotic Prophylaxis | 1 | 1999 | 79 | 0.050 |
Why?
| Primary Myelofibrosis | 1 | 2019 | 52 | 0.050 |
Why?
| Evidence-Based Medicine | 1 | 2021 | 436 | 0.050 |
Why?
| Oral Health | 1 | 2018 | 10 | 0.050 |
Why?
| Double-Blind Method | 3 | 2016 | 1829 | 0.040 |
Why?
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 11 | 0.040 |
Why?
| Myoepithelioma | 1 | 2017 | 11 | 0.040 |
Why?
| Metals | 1 | 2018 | 87 | 0.040 |
Why?
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2017 | 23 | 0.040 |
Why?
| Laryngectomy | 1 | 2017 | 25 | 0.040 |
Why?
| Surgical Wound Infection | 2 | 1999 | 183 | 0.040 |
Why?
| Multivariate Analysis | 2 | 2011 | 968 | 0.040 |
Why?
| Parotid Gland | 1 | 2017 | 33 | 0.040 |
Why?
| Statistics, Nonparametric | 2 | 2009 | 312 | 0.040 |
Why?
| Adenocarcinoma, Clear Cell | 1 | 2017 | 58 | 0.040 |
Why?
| Oncogene Proteins, Fusion | 1 | 2017 | 118 | 0.040 |
Why?
| Mutation | 2 | 2020 | 3737 | 0.040 |
Why?
| Probability | 2 | 2008 | 346 | 0.040 |
Why?
| Otitis Media | 1 | 1996 | 13 | 0.040 |
Why?
| Translocation, Genetic | 1 | 2017 | 260 | 0.040 |
Why?
| Loss of Heterozygosity | 1 | 2016 | 84 | 0.040 |
Why?
| Otitis Media with Effusion | 1 | 1995 | 7 | 0.040 |
Why?
| Pyrazoles | 1 | 2017 | 162 | 0.040 |
Why?
| Analgesics, Opioid | 1 | 2020 | 373 | 0.040 |
Why?
| Cutaneous Fistula | 1 | 1995 | 11 | 0.040 |
Why?
| Cellulitis | 1 | 1995 | 22 | 0.040 |
Why?
| Cephalosporins | 1 | 1995 | 39 | 0.040 |
Why?
| Pyridines | 1 | 2017 | 300 | 0.040 |
Why?
| Dissection | 1 | 1995 | 46 | 0.040 |
Why?
| Magnetic Resonance Imaging | 3 | 2017 | 3149 | 0.040 |
Why?
| Human papillomavirus 18 | 1 | 2014 | 15 | 0.040 |
Why?
| Costs and Cost Analysis | 1 | 1995 | 149 | 0.030 |
Why?
| Human papillomavirus 16 | 1 | 2014 | 36 | 0.030 |
Why?
| Protein Interaction Maps | 1 | 2014 | 49 | 0.030 |
Why?
| Sex Factors | 1 | 2018 | 1046 | 0.030 |
Why?
| Drug Costs | 1 | 1995 | 60 | 0.030 |
Why?
| Hospital Costs | 1 | 1995 | 99 | 0.030 |
Why?
| Administration, Oral | 1 | 2016 | 700 | 0.030 |
Why?
| Electromyography | 1 | 1994 | 169 | 0.030 |
Why?
| Drug Resistance, Neoplasm | 1 | 2017 | 553 | 0.030 |
Why?
| Amoxicillin-Potassium Clavulanate Combination | 3 | 1999 | 4 | 0.030 |
Why?
| Clavulanic Acids | 3 | 1999 | 4 | 0.030 |
Why?
| Societies, Medical | 1 | 2017 | 558 | 0.030 |
Why?
| Amoxicillin | 3 | 1999 | 14 | 0.030 |
Why?
| DNA Copy Number Variations | 1 | 2014 | 174 | 0.030 |
Why?
| Multicenter Studies as Topic | 1 | 2013 | 146 | 0.030 |
Why?
| Electric Stimulation | 1 | 1994 | 365 | 0.030 |
Why?
| Age Factors | 1 | 2018 | 1842 | 0.030 |
Why?
| Rabbits | 1 | 1994 | 706 | 0.030 |
Why?
| Platinum | 1 | 2012 | 58 | 0.030 |
Why?
| Aorta, Abdominal | 2 | 1990 | 60 | 0.030 |
Why?
| Phenotype | 1 | 2019 | 2226 | 0.030 |
Why?
| Organ Sparing Treatments | 1 | 2011 | 34 | 0.030 |
Why?
| Length of Stay | 1 | 1995 | 680 | 0.030 |
Why?
| Supraglottitis | 1 | 2011 | 3 | 0.030 |
Why?
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 183 | 0.030 |
Why?
| Glutamates | 1 | 2011 | 88 | 0.030 |
Why?
| Leucovorin | 1 | 2010 | 208 | 0.030 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2011 | 145 | 0.030 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2012 | 240 | 0.030 |
Why?
| Osteoradionecrosis | 1 | 2010 | 14 | 0.030 |
Why?
| Guanine | 1 | 2011 | 200 | 0.030 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 291 | 0.030 |
Why?
| Interferon-alpha | 1 | 2010 | 234 | 0.030 |
Why?
| Postoperative Period | 1 | 2010 | 300 | 0.020 |
Why?
| Laryngoscopy | 1 | 2009 | 36 | 0.020 |
Why?
| Deoxycytidine | 1 | 2011 | 225 | 0.020 |
Why?
| Siblings | 1 | 2010 | 102 | 0.020 |
Why?
| Camptothecin | 1 | 2010 | 193 | 0.020 |
Why?
| Treatment Failure | 1 | 2010 | 290 | 0.020 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2009 | 199 | 0.020 |
Why?
| Transforming Growth Factor alpha | 1 | 2009 | 51 | 0.020 |
Why?
| Postoperative Complications | 1 | 1999 | 2189 | 0.020 |
Why?
| Syndrome | 1 | 2010 | 426 | 0.020 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 79 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2009 | 369 | 0.020 |
Why?
| Bone Marrow Cells | 1 | 2010 | 251 | 0.020 |
Why?
| Arteriosclerosis | 1 | 1988 | 158 | 0.020 |
Why?
| Hypersensitivity | 1 | 2009 | 140 | 0.020 |
Why?
| Recombinant Proteins | 1 | 2010 | 1021 | 0.020 |
Why?
| Bacterial Infections | 1 | 2010 | 222 | 0.020 |
Why?
| Neoplasm Metastasis | 1 | 2012 | 1021 | 0.020 |
Why?
| Lymphatic Metastasis | 1 | 2009 | 492 | 0.020 |
Why?
| Regression Analysis | 1 | 2009 | 599 | 0.020 |
Why?
| Autoantibodies | 1 | 2008 | 250 | 0.020 |
Why?
| Cranial Sinuses | 1 | 2006 | 13 | 0.020 |
Why?
| Odds Ratio | 1 | 2008 | 653 | 0.020 |
Why?
| Blood Vessel Prosthesis | 1 | 1988 | 223 | 0.020 |
Why?
| Neoplasm Proteins | 1 | 2010 | 529 | 0.020 |
Why?
| Comorbidity | 1 | 2009 | 894 | 0.020 |
Why?
| Endothelium, Vascular | 1 | 1988 | 426 | 0.020 |
Why?
| Cerebrovascular Circulation | 1 | 2006 | 208 | 0.020 |
Why?
| Prevalence | 1 | 2008 | 1220 | 0.020 |
Why?
| Coronary Artery Disease | 1 | 1988 | 355 | 0.020 |
Why?
| Preoperative Care | 1 | 2006 | 400 | 0.020 |
Why?
| Signal Transduction | 1 | 2014 | 3177 | 0.020 |
Why?
| Algorithms | 1 | 2011 | 1766 | 0.010 |
Why?
| Registries | 1 | 2006 | 659 | 0.010 |
Why?
| Asthma | 1 | 2009 | 851 | 0.010 |
Why?
| Vascular Endothelial Growth Factors | 1 | 2001 | 57 | 0.010 |
Why?
| Case-Control Studies | 1 | 2006 | 1763 | 0.010 |
Why?
| Ticarcillin | 1 | 1999 | 2 | 0.010 |
Why?
| Mouthwashes | 1 | 1999 | 5 | 0.010 |
Why?
| Ampicillin | 1 | 1999 | 28 | 0.010 |
Why?
| Administration, Topical | 1 | 1999 | 95 | 0.010 |
Why?
| Injections, Intravenous | 1 | 1999 | 254 | 0.010 |
Why?
| Infant | 2 | 1996 | 3007 | 0.010 |
Why?
| Child, Preschool | 2 | 1996 | 3642 | 0.010 |
Why?
| Pilot Projects | 1 | 1999 | 798 | 0.010 |
Why?
| Suspensions | 1 | 1996 | 8 | 0.010 |
Why?
| Animals | 2 | 1994 | 26044 | 0.010 |
Why?
| Bacteria | 1 | 1999 | 451 | 0.010 |
Why?
| Acute Disease | 1 | 1996 | 833 | 0.010 |
Why?
| Back Pain | 1 | 1990 | 35 | 0.010 |
Why?
| Hematoma | 1 | 1990 | 91 | 0.010 |
Why?
| 6-Ketoprostaglandin F1 alpha | 1 | 1988 | 6 | 0.010 |
Why?
| Polytetrafluoroethylene | 1 | 1988 | 69 | 0.010 |
Why?
| Microscopy, Electron, Scanning | 1 | 1988 | 155 | 0.010 |
Why?
| Jugular Veins | 1 | 1988 | 69 | 0.010 |
Why?
| Omentum | 1 | 1988 | 67 | 0.010 |
Why?
| Microcirculation | 1 | 1988 | 102 | 0.010 |
Why?
| Dogs | 1 | 1988 | 785 | 0.010 |
Why?
| Aorta | 1 | 1988 | 294 | 0.010 |
Why?
| Thrombosis | 1 | 1988 | 258 | 0.000 |
Why?
|
|
Blair's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|